

5-1-2018


## Clinico-pathological features and PD-1/PD-L1 Expression in Primary Mediastinal Large B Cell Lymphoma

Lydia Glick  
*Thomas Jefferson University*

Geetha Jagannathan, MD  
*Thomas Jefferson University*

Guldeep Uppal, MD  
*Thomas Jefferson University*

Follow this and additional works at: <https://jdc.jefferson.edu/phsrs>

 Part of the [Medical Anatomy Commons](#), [Medical Cell Biology Commons](#), and the [Medical Pathology Commons](#)

[Let us know how access to this document benefits you](#)

### Recommended Citation

Glick, Lydia; Jagannathan, MD, Geetha; and Uppal, MD, Guldeep, "Clinico-pathological features and PD-1/PD-L1 Expression in Primary Mediastinal Large B Cell Lymphoma" (2018). *Department of Pathology Honors Program Student Research Symposium*. Poster 42.

<https://jdc.jefferson.edu/phsrs/42>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Pathology Honors Program Student Research Symposium by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

## **Clinico-pathological features and PD-1/PD-L1 Expression in Primary Mediastinal Large B Cell Lymphoma**

Lydia Glick, Geetha Jagannathan, and Guldeep Uppal

Department of Pathology, Anatomy & Cell Biology, Division of Hematopathology  
Thomas Jefferson University, Philadelphia

Primary Mediastinal Large B Cell Lymphoma (PMBCL) is a distinct subtype of Diffuse Large B Cell Lymphoma (DLBCL) that has been historically reported to have a worse prognosis than DLBCL. Occasional studies have reported PD-L1 expression in PMBCL, which can emerge as an important target for immune-check point therapy. This study aimed to evaluate clinico-pathological features and characterize the expression of PD-1 and PD-L1 in a single cohort of 15 patients with PMBCL.

A total of 15 cases of PMBCL were retrieved from records of the department of Pathology; eleven of these had tissue available for additional immunohistochemistry, specifically, PD-L1 (clone SP142) and PD-1 (clone NAT105). A cut-off of  $\geq 30\%$  was used for PD-1 and PDL-1 expression in tumor cells, and  $\geq 20\%$  for tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs).

The median age was 42 years (23-83 years), and 9 of 15 (60%) patients were females. Of the 8 patients with clinical data, three (38%) received aggressive R-EPOCH therapy and responded. Tumor cells showed positive PD-L1 expression in only 1 case (9%), and TAMs showed positive PDL-1 expression in seven cases (64%). None of the cases analyzed showed positive PD-1 expression in TCs, while four cases (36%) showed positive PD-1 expression in TILs.